A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find out if Procrit (epoetin alfa) will help
decrease the need for blood transfusions in patients who have Acute Myelogenous Leukemia
(AML) or High-risk Myelodysplastic Syndrome (MDS) and are receiving chemotherapy. Researchers
also want to learn about the remission rates (rates of recovery) in patients with cancer who
have received treatment with epoetin alfa. The safety and effectiveness of this therapy will
also be studied.